Vascular endothelial cells targeted Tyr-RGD-PEG-PEI nano-drug synthesis and its biological activity

Yaoxue Xuebao

Volumn 44, Issue 9, 2009, Pages 1034-1039

  Gao, Yong ^a   He, Sheng Li ^c   Zhong, Gao Ren ^c   Cai, Hong Pei ^b   Li, Qi ^a  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Endothelial cell; Integrin; Nanoparticle; siRNA; Tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; NANOCARRIER; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BIOLOGICAL ACTIVITY; DRUG DISTRIBUTION; DRUG SYNTHESIS; ENCAPSULATION; ENDOTHELIUM CELL; GENE VECTOR; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; TARGET CELL; THIN LAYER CHROMATOGRAPHY; TUMOR MODEL;

ANIMALS; ENDOTHELIAL CELLS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTEGRINS; MICE; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; RNA, SMALL INTERFERING;

EID: 71049152419     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo [J]. Mol Cancer Ther, 2007, 6: 833-843. (Pubitemid 46554553)
2. Zhang C, Newsome JT, Mewani R, et al. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs [J]. Methods Mol Biol, 2009, 480: 65-83.
3. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo [J]. Cancer Res, 2002, 62: 5139-5143. (Pubitemid 35024582)
4. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle [J]. Nucl Acids Res, 2004, 32: e149.
5. Decristoforo C, Faintuch-Linkowski B, Rey A. [99mTc] HYNIC-RGD for imaging integrin alphavbeta3 expression [J]. Nucl Med Biol, 2006, 33: 945-952.
6. de Wolf HK, Snel CJ, Verbaan FJ, et al. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration [J]. Int J Pharm, 2007, 331: 167-175.
7. Golshayan AR, George S, Heng DY. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy [J]. J Clin Oncol, 2009, 27: 235-241.
8. Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J]. N Engl J Med, 2008, 359: 1757-1765.
9. Zhu J, Tang A, Law LP, et al. Amphiphilic core- shell nanoparticles with poly (ethylenimine) shells as potential gene delivery carriers [J]. Bioconjug Chem, 2005, 16: 139-146. (Pubitemid 40129687)
10. Neu M, Germershaus O, Behe M, et al. Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo [J]. J Control Release, 2007, 124: 69-80.
11. Glodde M, Sirsi SR, Lutz GJ. Physiochemical properties of low and high molecular weight poly(ethylene glycol)-grafted Polyethylene imine) copolymers and their complexes with oligonucleotides [J]. Biomacromolecules, 2006, 7: 347-356. (Pubitemid 43154513)
12. Gharwan H, Wightman L, Kircheis R, et al. Nonviral gene transfer into fetal mouse livers (a comparison betneen cationic polymer PEI and naked DNA) [J]. Gene Ther, 2003, 10: 810-817. (Pubitemid 36621826)
13. Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery [J]. Pharm Res, 2005, 22: 1-10. (Pubitemid 40558140)